Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
547M
Biotechnology
Next Earning date - 05 Mar 2025
547M
Biotechnology
Next Earning date - 05 Mar 2025
Relative Strenght
93Volume Buzz
28%Earning Acce
YesDist 52w H.
5%